Soligenix (NASDAQ:SNGX) Earns “Sell (E+)” Rating from Weiss Ratings

Soligenix (NASDAQ:SNGX)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other brokerages also recently issued reports on SNGX. Wall Street Zen downgraded shares of Soligenix to a “strong sell” rating in a research note on Saturday, August 16th. Alliance Global Partners cut their target price on shares of Soligenix from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, July 16th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.00.

Soligenix Price Performance

Soligenix stock opened at $1.81 on Wednesday. The firm has a 50-day moving average of $2.63 and a 200-day moving average of $2.07. Soligenix has a one year low of $1.09 and a one year high of $6.23. The company has a market cap of $7.76 million, a price-to-earnings ratio of -0.48 and a beta of 1.95.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.03). As a group, sell-side analysts expect that Soligenix will post -4.65 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Soligenix stock. Connective Capital Management LLC purchased a new stake in Soligenix Inc. (NASDAQ:SNGX) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 101,633 shares of the biopharmaceutical company’s stock, valued at approximately $219,000. Connective Capital Management LLC owned 3.11% of Soligenix as of its most recent SEC filing. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.